Table 1.
Model Parameters
| Parameter | Base-Case Value | Sensitivity Analysis | Source |
|---|---|---|---|
| Starting Age | 60 | 13,23 | |
| Dose SSA |
Octreotide LAR 20 mg/28 days Octreotide 60 mg with PRRT |
38–40 | |
| Costs | |||
| Cost SSA | $4121/month for Octreotide | $2060–$8242 | 28 |
| Cost PRRT | $205,200 | $102,600-410,400 | 31,41 |
| Complication, Mortality and Progression Estimates | |||
| Rate of Complications from SSA | 1% over 96 weeks | +/− 25% | 13,23 |
| All cause mortality | CDC Life Tables | 32 | |
| Rate of NET related death, untreated | 18 month median survival | +/−25% | 25,33 |
| Rate of NET related death, on SSA | 39 month median survival | +/−25% | 25,33 |
| Rate of NET related death, on PRRT | 39 month median survival | +/−25% | 37,42 |
| Rate of progression, off SSA | 6 month median | +/−25% | 13,23 |
| Rate of progression, on SSA | 14 month median | +/−25% | 13,23 |
| Rate of progression after delaying initiation of SSA | 14 month median | +/−25% | 24,37 |
| Utilities | |||
| Quality of Life pre SSA | 0.79 | +/−0.1 | 34,35,43 |
| Quality of Life on SSA | 0.79 | +/−0.1 | 34,43 |
| Quality of Life with disease progression | 0.72 | +/−0.1 | 34 |
| Quality of Life with uncontrolled symptoms | 0.32 | +/−0.1 | 36,44 |
SSA somatostatin analogues; PRRT Peptide Receptor Radionuclide Therapy; NET neuroendocrine tumor